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Abstract
Background: Mucopolysaccharidosis type IIIA (MPS IIIA) is the most common of the
mucopolysaccharidoses. The disease is caused by a deficiency of the lysosomal enzyme
sulphamidase and results in the storage of the glycosaminoglycan (GAG), heparan sulphate. MPS
IIIA is characterised by widespread storage and urinary excretion of heparan sulphate, and a
progressive and eventually profound neurological course. Gene therapy is one of the few avenues
of treatment that hold promise of a sustainable treatment for this disorder.
Methods: The murine sulphamidase gene cDNA was cloned into a lentiviral vector and high-titre
virus produced. Human MPS IIIA fibroblast cultures were transduced with the sulphamidase vector
and analysed using molecular, enzymatic and metabolic assays. High-titre virus was intravenously
injected into six 5-week old MPS IIIA mice. Three of these mice were pre-treated with
hyperosmotic mannitol. The weight of animals was monitored and GAG content in urine samples
was analysed by polyacrylamide gel electrophoresis.
Results: Transduction of cultured MPS IIIA fibroblasts with the sulphamidase gene corrected both
the enzymatic and metabolic defects. Sulphamidase secreted by gene-corrected cells was able to
cross correct untransduced MPS IIIA cells. Urinary GAG was found to be greatly reduced in
samples from mice receiving the vector compared to untreated MPS IIIA controls. In addition, the
weight of treated mice became progressively normalised over the 6-months post-treatment.
Conclusion: Lentiviral vectors appear promising vehicles for the development of gene therapy for
MPS IIIA.
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The mucopolysaccharidoses (MPS) are a group of lyso-
somal storage disorders that arise from deficiencies in the
catabolism of glycosaminoglycans (GAG) [1]. At present
there are eleven known MPS, each resulting from the defi-
ciency of a different lysosomal enzyme. Of the MPS, MPS
IIIA (Sanfillipo A syndrome) is one of the most common,
and as far as treatment goes, one of the most intractable,
in that central nervous system (CNS) pathology is para-
mount [1]. Severely affected patients usually present by 2–
3 years of age with a range of symptoms related to CNS
pathology. These symptoms include delayed develop-
ment, hyperactivity, aggressive behaviour, and sleep dis-
turbances. Other symptoms include hirsutism and
diarrhoea. The somatic manifestations of the disease,
which include skeletal pathology, hepatosplenomegaly
and joint stiffness, are generally milder and are more com-
monly found in older patients. MPS IIIA results from a
genetically determined deficiency of sulphamidase, a lys-
osomal enzyme which normally catalyses the cleavage of
N-linked sulphate from glucosamine residues at the non-
reducing terminus of heparan sulphate. As this represents
an obligatory step in the degradation of heparan sulphate,
elevated levels of heparan sulphate fragments are found in
tissues and in the urine. MPS IIIA also results in the sec-
ondary storage of GM2 and GM3 gangliosides in the CNS.
MPS IIIA represents a useful paradigm for therapies aimed
at treating the widespread pathology which is found in
many of the MPS. The availability of small (mouse) [2]
and large (dog) [3,4] animal models of MPS IIIA provides
a useful experimental resource for the preclinical develop-
ment and testing of therapies.
The MPS IIIA mouse [2], the result of a spontaneous
mutation, shows many of the progressive pathological
features found in the human disease. By 6–7 months of
age affected mice are noticeably less active, develop a
scruffy appearance, hunched posture and abdominal dis-
tension, and lifespan is shortened. Affected animals show
elevated levels of urinary GAG, which is predominantly
heparan sulphate, greatly decreased sulphamidase activity
in all tissues, normal or supranormal levels of other lyso-
somal enzymes and widely distributed storage. MPS IIIA
mice are also significantly heavier than normals. The MPS
IIIA mouse therefore provides an excellent model for the
initial analysis of gene therapy strategies for the MPS in
general, and MPS IIIA in particular.
Although intravenous enzyme replacement therapy has
now been developed for a number of the MPS, it is obvi-
ous that this approach is not a viable option for treatment
of CNS pathology due to its effective partitioning from the
peripheral circulation by the blood-brain barrier [5].
Alternative therapies for MPS CNS pathology include
small molecule therapies, aimed at preventing synthesis
of storage material [6,7], and gene replacement therapy
[7]. There is also accumulating evidence that the blood-
brain barrier is not completely impermeable to lysosomal
enzymes, and that high levels of enzyme in the peripheral
circulation, delivered either by enzyme replacement ther-
apy [8], or via gene therapy [9], result in delivery of signif-
icant amounts (i.e. high enough to affect pathology) of
enzyme to the CNS.
Gene replacement therapy holds obvious potential for the
treatment of the MPS [7,10,11], including MPS IIIA. We
have previously demonstrated retroviral-mediated gene
correction of cultured MPS IIIA fibroblasts [12]. However,
retroviruses have serious limitations [13] that preclude
their use in gene delivery to the CNS, and make them of
limited utility in the transduction of any tissue in vivo. In
order to further the development of gene therapy for MPS
IIIA we have developed a lentiviral vector that expresses
the murine sulphamidase gene and shown that it can be
used to correct MPS IIIA cells in vitro. After intravenous
administration of the vector to MPS IIIA mice urinary
GAG and the weight of treated mice became progressively
normalised over the 6-month period following vector
administration.
Materials and methods
PCR
The primers used for amplification of the murine sul-
phamidase gene were msulatg (GGGCCCATCGAT-
GCCACC ATGCACTGCCCGGGACTGGCCTG); msulbglr
(GAGGGTCGTAGATCTGGGGTGTCC); msulbglf
(GGACACCCCAGATCTACGACCCTC) and msultga
(GGGCCCGAATTC TCAGAGTTCATTGTGAAGCGGTC).
Sequences homologous to the murine sulphamidase gene
sequence are shown in italics. The reaction conditions for
all PCRs were 94°C, 30 seconds, 60°C, 20 seconds and
68°C, 1 minute for 20 cycles and used the Expand High
Fidelity system (Roche). First strand cDNA from NIH3T3
cells (ATCC CRL-1658) was used as template. A 648 bp
fragment corresponding to the 5' part of the murine sul-
phamidase cDNA sequence was amplified with the prim-
ers msulatg and msulbglr, and cloned as a ClaI/BglII
fragment in pSP70 (Progen). A 872 bp fragment corre-
sponding to the 3' part of the sequence was amplified with
the primers msulbglf and msultga and cloned as an BglII/
EcoRI fragment, again in pSP70.
Lentiviral vector
The lentiviral vector used in this study was essentially the
same as the pAF2Δ-SE vector [14] except that the SV40
early promoter was replaced with the murine phos-
phoglycerate kinase gene promoter from MSCVpac [15] to
give pHIV-1pgkEYFPPage 2 of 8
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The production and purification of the virus used in this
work has been described elsewhere [16]. The virus was
resuspended in 0.9% (w/v) NaCl and quantified by p24
ELISA (NEN-Dupont). Virus for in vivo administration was
shown to be negative for replication competent virus [14].
Cell culture, transduction, and enzymatic and metabolic 
analysis
Normal and MPS IIIA human skin fibroblasts were plated
in 6-well plates and grown till confluent in DMEM/10%
(v/v) FCS (2 mL per well). The medium was then aspi-
rated and the cells fed with 1.5 mL of DMEM/10% (v/v)
FCS containing 8 μg/mL polybrene. MPS IIIA cells were
then transduced with vector for 24 hours. The medium
was then exchanged for growth medium. For analysis,
medium was exchanged for Ham's F12/10% (v/v) FCS,
and after 4 hours the medium was exchanged again for
Ham's F12/10% (v/v) FCS containing 10 μCi/ml 35SO4; a
further 24 hours later the label was removed and the cells
fed with DMEM/10% (v/v) FCS. To assess enzymatic
cross-correction, labelled MPS IIIA cells were exposed to
medium collected from lentivirus-transduced cells for 24
hours. For analysis of storage, cells were harvested 72
hours after labelling and cell lysates prepared by freeze/
thaw in 20 mM Tris-HCl, pH 7.0, 500 mM NaCl. The cell
lysates were then clarified by microcentrifugation (13,000
g, 5 minutes) and the supernatants assayed for sulphami-
dase [17] and β-hexosaminidase [18] activity, total pro-
tein and 35S cpm. The pellets resulting from the
microcentrifugation of the freeze/thaw cell lysates were
used to prepare genomic DNA using the Promega Wizard
SV Genomic DNA kit.
Real time PCR analysis
Vector sequences were detected in genomic DNA using a
TaqMan assay for gag gene sequences present in the vector
(Forward primer 5' AGCTAGAACGATTCGCAGTTGAT 3',
reverse primer 5' CCAGTATTTGTCTACAGCCTTCTGA 3',
probe 5' CCTGGCCTGTTAGAAAC 3' with FAM/NFQ
reporter). Results were normalized using a single copy
sequence in the transferrin gene (Forward primer 5' AAG-
CAGCCAAATTAGCATGTTGAC 3', reverse primer 5'
GGTCTGATTCTCTGTTTAGCTGACA 3', probe 5'
CTGGCCTGAGCTCCT 3' with FAM/NFQ reporter). The
assays were run under standard conditions and using
Applied biosystems TaqMan Universal PCR Master Mix.
DNA from an A549 derived cell line, and containing a sin-
gle copy of the lentiviral vector, was used to provide an
absolute standard for copy number. Real time PCR was
performed on an ABI 7300 cycler and analyzed using
Sequence Detection Software v1.2.2 (Applied Biosys-
tems). All samples were analyzed in triplicate.
Treatment of MPS IIIA mice
The MPS IIIA mouse colony was originally established
from mice provided by Dr. P. Stanley (Albert Einstein
Institute College Medicine, New York). The mice were
housed in the Women's and Children's Hospital Animal
Care Facility where general maintenance was provided by
trained animal care staff. MPS IIIA and normal mice were
genotyped by PCR using previously established methods
[19]. Six 5-week old male MPS IIIA mice were injected
with 50 μg p24 equivalent of the lentiviral vector via injec-
tion into the tail vein. Three mice were pre-treated by
intravenous injection of hyperosmotic mannitol (200 μl
of 25% (w/v) mannitol in saline) 5 minutes prior to the
administration of the vector in an attempt to achieve vec-
tor delivery to the CNS.
Analysis of urinary GAG
Samples of mouse urine were incubated for one hour at
37°C with two volumes of 0.1% cetylpyridinium chloride
in 0.054 M Na3 citrate (pH 4.8). Samples were centrifuged
for 10 minutes at 3000 rpm and pellets were resuspended
in 150 μL 2 M LiCl. Following addition of 800 μL absolute
ethanol, samples were incubated at -20°C for one hour
and then centrifuged for 10 minutes at 3000 rpm. Pellets
were resuspended in 200 μL of water, lyophilised, and
then resuspended in 20 μL water.
Purified glycosaminoglycan samples (0.2 μmol creatinine
equivalents) were analysed on 40–50% linear gradient
polyacrylamide gels as previously described [20].
Statistical analysis
Except for weight data, results were analysed using one
way ANOVA/SNK [21].
Mouse weights were analysed by comparison of non-lin-
ear trends for each group. Firstly, the relationship between
body weight and age for each group was modelled using a
cubic smoothing spline. Modelling using different non-
linear trends for each group was then compared with
modelling using the same non-linear trend for all groups
and the log-likelihood values compared to determine sig-
nificance. Where significance was found prediction inter-
vals were calculated for the splines to determine the ages
at which the groups were significantly different. In age
intervals where predicted values for a group did not over-
lap the predicted interval for another group the treatment
groups being compared were taken as being significantly
different (p < 0.001).Page 3 of 8
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Isolation of the murine sulphamidase cDNA sequence and 
construction of lentiviral vectors transducing murine 
sulphamidase
The murine sulphamidase cDNA sequence was PCR
amplified in two parts as described in Materials and meth-
ods. The 5' primer used to amplify the 5' part of the
sequence was designed to introduce a Kozak consensus
sequence immediately prior to the initiation codon. DNA
sequencing was used to confirm the absence of PCR
induced errors. The two fragments were then joined via
the common BglII site to generate a full length sequence.
The full length sequence was then cloned into the pHIV-
1pgk vector placing it under the transcriptional control of
the pgk promoter (Fig. 1). The resulting construct was des-
ignated pHIV-1pgkmsulp
Correction of MPS IIIA skin fibroblasts, metabolic analysis
MPS IIIA skin fibroblasts were transduced with 68, 167 or
508 ng p24 equivalent of the pHIV-1pgkmsulph vector per
well (6-well plate) as described in Materials and methods.
Labelling with 35SO4 demonstrated that all vector trans-
duced cells were metabolically normalised (Fig. 2), as
were cells exposed to medium collected from cells trans-
duced with 508 ng p24 equivalent of vector (Fig. 2). This
medium contained 16 pmol/min/ml of sulphamidase
activity. Conditioned medium from control MPS IIIA cells
did not contain detectable sulphamidase activity. In all
cases storage was significantly different from control MPS
IIIA cells (P < 0.01) and not significantly different from
control normal cells (P > 0.05).
Correction of MPS IIIA skin fibroblasts, enzymatic analysis
Analysis of the levels of sulphamidase activity (Fig. 3)
showed that the level of enzyme replacement increased
with increasing amounts of vector added, with the two
larger amounts effectively normalizing enzyme levels. In
comparison to untransduced MPS IIIA cells, the increase
in activity with the smallest amount of virus (68 ng p24)
was insignificant, while the increase in sulphamidase
activity with the two larger amounts of virus (167 and 508
ng p24) was significant (P < 0.01). The correction in
enzyme activity in the cultures transduced with 167 ng
p24 of vector was not significantly different from the level
found in normal cells (P > 0.05), while enzyme activity
resulting from transduction with 508 ng p24 of vector was
significantly higher (P < 0.05) than in the normal control
cells. β-hexosaminidase was not significantly different in
any of the samples (P > 0.05). In the cross-correction
experiments, sulphamidase activity in cells exposed to
conditioned medium from transduced cells was not
detectable above background.
Correction of MPS IIIA skin fibroblasts, real time PCR 
analysis
Real time PCR analysis of DNA samples from transduced
fibroblasts revealed the vector copy number to be propor-
tional (R2 = 0.99) to the dose of virus used (Fig. 4). The
copy number varied from 0.3 copies/cell (68 ng p24 dose)
to 1.7 copies/cell (508 ng p24 dose). No vector was
detected in un-transduced cells or cells exposed to condi-
tioned medium collected from transduced cells. Enzyme
expression was proportional (R2 = 0.90) to virus dose (Fig.
4), and hence also to vector copy number (R2 = 0.95).
In vivo administration of vector, analysis of urinary GAG 
and body weight
Six 5 week old MPS IIIA mice (animal #s 2, 3, 7, 94, 98
and 99) were intravenously injected with vector as
described in Materials and methods. Three of these mice
(#s 2, 3 and 7) also received hyperosmotic mannitol
immediately prior to administration of the vector. At var-
ious times post treatment urine was collected, GAG puri-
fied by CPC precipitation and analysed by gradient-PAGE
Schematic representation of pHIV-1pgkmsulp lentiviral vectorFigure 1
Schematic representation of pHIV-1pgkmsulp lentiviral vector. Schematic of pHIV-1pgkmsulp lentiviral vector show-
ing pertinent elements. L, long terminal repeat, gag, gag gene sequence; rre, Rev-response element; c, central polypurine tract; 
pgk, murine phosphoglycerate kinase gene promoter; sulphamidase, murine sulphamidase cDNA sequence.
sulphamidasepgkrreL Lcgag
1 kbPage 4 of 8
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analysis show that there is a large and consistent reduction
in urinary GAG to normal, or near normal levels, in the
treated animals (Fig 5). Comparison of samples taken
from individual animals at different time points suggest
that the reduction in urinary GAG becomes more marked
after a longer period of treatment (e.g. animal 2, 122 days
versus 54 days after treatment).
At the time of treatment all animals showed the weight
gain typical of MPS IIIA affected mice. However, over the
6-month treatment period their weight progressively
trended towards normal and became closer to the normal
range than to the range seen in untreated mice (Fig 6). No
difference in growth was seen between the mice given
hyperosmotic mannitol prior to treatment and those that
were not (data not shown). Accordingly, the treated mice
were analysed as one group. Statistical analysis showed
that the weight of treated mice was significantly different
from that of untreated mice after age 54 days (17–22 days
post-treatment), and not significantly different from nor-
mal after age 166 days (18.5–19 weeks post-treatment).
Discussion
Gene replacement therapy for the MPS has several poten-
tial advantages over enzyme replacement therapy, the cur-
rent gold-standard for treatment where it is available.
These include a reduced frequency of treatment, better
efficacy and the prospect of being able to treat CNS dis-
ease by the introduction of gene vectors directly into the
CNS. Until recently, the development of gene therapy for
the MPS has foundered on the lack of suitable gene deliv-
ery vehicles. Generally, integrative vectors would seem to
be preferable for inherited metabolic disorders such as the
MPS as they confer genetic stability on the transduced
gene and hence the potential for long-term effects.
Because of this, retroviral vectors have long been the gene
delivery vehicle of choice. However, vectors derived from
oncogenic retroviral vectors are unable to transduce non-
cycling cells [13], severely limiting their usefulness. For
this reason we, and others, have developed lentiviral vec-
tors [14,22-25]. These have the general positive attributes
of retroviral vectors with the additional feature of being
able to transduce non-cycling cells, meaning they have
great utility for in vivo gene delivery. This has led to the use
Correction of MPS IIIA enzymatic phenotype in vitroFigure 3
Correction of MPS IIIA enzymatic phenotype in 
vitro. MPS IIIA cells were transduced with 68, 167 or 508 ng 
p24 equivalent of the pHIV-1pgkmsulp vector and cell lysates 
assayed for sulphamidase activity as described in Materials 
and methods (Gene transduction). Conditioned medium from 
the cells transduced with 508 ng p24 equivalent of vector 
was added to untransduced cells (cross correction), and again, 
cell lysates assayed for sulphamidase activity. Normal and 
untransduced MPS IIIA cells were used as controls.
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Correction of MPS IIIA storage phenotype in vitroFigure 2
Correction of MPS IIIA storage phenotype in vitro. 
MPS IIIA cells were transduced with 68, 167 or 508 ng p24 
equivalent of the pHIV-1pgkmsulp vector and cell lysates 
assayed for incorporation of 35SO4 as described in Materials 
and methods (Gene transduction). Conditioned medium from 
the cells transduced with 508 ng p24 equivalent of vector 
was added to untransduced cells (cross correction), and again, 
cell lysates assayed for incorporation of 35SO4. Normal and 
untransduced MPS IIIA cells were used as controls.
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Genetic Vaccines and Therapy 2007, 5:1 http://www.gvt-journal.com/content/5/1/1of lentiviral vectors in the development of gene therapy
for a range of disorders, including the MPS [26-29].
In this study we have constructed a lentiviral vector and
demonstrated proof of principle experiments in vitro.
Human cells were used for these experiments simply for
convenience; they were immediately available while cul-
tures of control and MPS IIIA murine fibroblasts were not.
Lentiviral-mediated gene delivery to human MPS IIIA skin
fibroblasts resulted in correction of the metabolic and
enzymatic defects exhibited by these cells, even at the low-
est dose of virus used. In addition, the complete correc-
tion of the metabolic defect in cultured MPS IIIA cells with
the lowest copy number of vector, and the fact that
medium secreted from gene corrected cells was able to
cross-correct the metabolic defect in non-transduced cells,
demonstrates the potential of gene therapy to affect mul-
tiple cells in addition to those directly transduced by vec-
tor. In the cross-correction experiment it was not possible
to assess whether enzyme uptake was via the mannose-6-
phosphate (M6P) receptor, as metabolic correction was
seen when enzyme was added in the presence or absence
of M6P (data not shown). In addition, sulphamidase
activity was too low to be detected in all samples from the
cross correction experiment. This, at least in part, reflects
the relatively low sensitivity of the enzyme assay, and in
part the relatively low levels of enzyme activity in the con-
Vector copy number in transduced MPS IIIA cellsFigure 4
Vector copy number in transduced MPS IIIA cells. 
MPS IIIA cells were transduced with 68, 167 or 508 ng p24 
equivalent of the pHIV-1pgkmsulp vector and both vector 
copy number, and sulphamidase enzyme activity, were deter-
mined as described in Materials and methods. Both vector 
copy number and enzyme levels are proportional to vector 
dose.
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Urine analysisFigure 5
Urine analysis. Urine from selected mice was analysed by gradient PAGE as described in Materials and methods. Lane M, 
octasaccharide size standard; lane 1, empty; lane 2, normal; lane 3, normal; lane 4, MPS IIIA; lane 5, MPS IIIA; lane 6, treated #2, 
54 days post-treatment; lane 7, treated #2, 122 days post-treatment; lane 8, treated #3, 67 days post-treatment; lane 9, treated 
#7, 61 days post-treatment; lane 10, treated #7, 196 days post-treatment; lane 11, treated #94, 106 days post-treatment; lane 
12, treated #98, 98 days post-treatment.
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that can be easily detected).
In the in vitro study the pgk promoter appears to be rela-
tively weak, as the level of expression obtained with the
vector was not greater than that found in normal cells,
suggesting it may be useful to assess the level of expression
from other promoters. However, the use of strong pro-
moters must be developed with caution as they increase
the risk of insertional mutagenesis via oncogene activa-
tion [30].
The development of a real time PCR assay for our vector,
and control cell line containing a single copy of our vec-
tor, will prove useful in further studies, for example deter-
mination of vector copy number in tissues after in vivo
administration. By careful selection of the vector
sequences that the real time PCR detects we have made
this assay generic so that it will detect all versions of our
vector, whatever the transgene or promoter sequence the
vector carries.
Vector was administered to MPS IIIA mice either with or
in the absence of a hyperosmotic mannitol pre-treatment.
In the studies presented in this paper these two sets of ani-
mals could not be distinguished, therefore, all animals
were grouped together for analysis. Administration of the
vector to MPS IIIA mice resulted in partial normalisation
of urinary GAG as evidenced by gradient PAGE analysis,
giving an early indication of in vivo efficacy. The power of
the gradient PAGE system [20] is that it allows the specific
assessment of the small to large size free GAG molecules
(i.e. four to thirty saccharide residues in length) typical of
lysosomal storage material, rather than small free GAG
(di- to tetra-saccharides) which can be analysed by mass
spectrometry, or the total (free and conjugated) GAG
measured by analysis of uronic acid.
The weight of the treated animals was also progressively
normalised, suggesting that the treatment is having a
widespread effect on the disease pathology even though
enzyme activity could not be detected in blood samples
from treated mice (data not shown). Further analysis of
these animals is ongoing and will be published elsewhere.
In conclusion, lentiviral vectors appear to be promising
reagents for the development of effective therapy for MPS
IIIA. Future work will involve in vivo delivery of the vector
to somatic and CNS cells and detailed analysis of the dis-
ease phenotype in treated animals.
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